Chimeric Therapeutics Ltd
Research Chimeric Therapeutics Ltd (CHM) on Bullrun: market cap AUD 1.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCHM
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 1.10M
- Financial periodFY2025
- RevenueAUD 3.97M
- Net income-AUD 10.43M
- Free cash flow-AUD 7.28M
- Gross margin78.7%
Valuation Snapshot
latest market cap is AUD 1.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 3.97M | -AUD 10.43M | -AUD 7.28M | 78.7% | -0.01 | AUD 5.76M | n/a | AUD 1.97M |
| FY2024 | n/a | -AUD 12.53M | -AUD 7.54M | n/a | -0.02 | AUD 3.05M | AUD 3.59M | AUD 2.47M |
| FY2023 | n/a | -AUD 25.50M | -AUD 16.42M | n/a | -0.06 | AUD 2.36M | n/a | AUD 6.08M |
| FY2022 | n/a | -AUD 14.62M | -AUD 13.67M | n/a | -0.04 | AUD 18.38M | n/a | AUD 26.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 1.10M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Chimeric Therapeutics Ltd's market cap?
Chimeric Therapeutics Ltd's market capitalization is AUD 1.10M.
What does Chimeric Therapeutics Ltd do?
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors.